Ilsung Chang
About
Ilsung Chang is a scholar working on Molecular Biology, Oncology and Organic Chemistry.
According to data from OpenAlex, Ilsung Chang has authored 34 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 22 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Ilsung Chang's work include Melanoma and MAPK Pathways (13 papers), Hedgehog Signaling Pathway Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ilsung Chang is often cited by papers focused on Melanoma and MAPK Pathways (13 papers), Hedgehog Signaling Pathway Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Ilsung Chang collaborates with scholars based in United States, United Kingdom and Italy. Ilsung Chang's co-authors include Antoni Ribas, Grant A. McArthur, Paolo A. Ascierto, James Larkin, Brigitte Dréno, Claus Garbe, Michele Maio, L. Thomas, Mario Mandalà and Gabriella Liszkay and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Ilsung Chang
34 papers receiving 2.6k citations
Hit Papers
Peers
Ilsung Chang
Victor Sandor United States
Jan Willem B. de Groot Netherlands
Kimberly B. Dahlman United States
Caroline Dutriaux France
Nicholas W. Choong United States
Gabriella Liszkay Hungary
Michael D. Pickard United States
Frank Wu United States
Lila Adnane United States
Jeff Sosman United States
Citations per year, relative to Ilsung Chang Ilsung Chang (= 1×)
peers
Victor Sandor
Countries citing papers authored by Ilsung Chang
Since
Specialization
Citations
This map shows the geographic impact of Ilsung Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilsung Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilsung Chang more than expected).
Fields of papers citing papers by Ilsung Chang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ilsung Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilsung Chang. The network helps show where Ilsung Chang may publish in the future.
Co-authorship network of co-authors of Ilsung Chang
This figure shows the co-authorship network connecting the top 25 collaborators of Ilsung Chang. A scholar is included among the top collaborators of Ilsung Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilsung Chang. Ilsung Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shapiro, Geoffrey I., Patricia LoRusso, Daniel C. Cho, et al.. (2020). A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Investigational New Drugs. 39(1). 163–174.
2.
Yan, Yibing, Matthew Wongchenko, Caroline Robert, et al.. (2019). Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic Melanoma. Clinical Cancer Research. 25(11). 3239–3246.
3.
Dréno, Brigitte, Paolo A. Ascierto, Victoria Atkinson, et al.. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma. British Journal of Cancer. 118(6). 777–784.
4.
Wongchenko, Matthew, Antoni Ribas, Paolo A. Ascierto, et al.. (2018). Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precision Oncology. 1–18.
5.
Wongchenko, Matthew, Grant A. McArthur, Brigitte Dréno, et al.. (2017). Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research. 23(17). 5238–5245.
6.
Chapman, Paul B., Caroline Robert, James Larkin, et al.. (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of Oncology. 28(10). 2581–2587.
7.
Larkin, James, Grant A. McArthur, Antoni Ribas, et al.. (2016). Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).. Journal of Clinical Oncology. 34(15_suppl). 9528–9528.
8.
Larkin, James, Paolo A. Ascierto, Brigitte Dréno, et al.. (2014). Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma. New England Journal of Medicine. 371(20). 1867–1876.
9.
Kaye, Stanley B., Louis Fehrenbacher, Robert W. Holloway, et al.. (2012). A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission. Clinical Cancer Research. 18(23). 6509–6518.
10.
Graham, Richard, Cornelis E. C. A. Hop, Marie T. Borin, et al.. (2012). Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. British Journal of Clinical Pharmacology. 74(5). 788–796.
11.
Graham, Richard, Ilsung Chang, Jin Y. Jin, et al.. (2012). Daily Dosing of Vismodegib to Steady State Does Not Prolong the Qtc Interval in Healthy Volunteers. Journal of Cardiovascular Pharmacology. 61(1). 83–89.
12.
LoRusso, Patricia, Charles M. Rudin, Josina C. Reddy, et al.. (2011). Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(8). 2502–2511.
13.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(17). 5774–5782.
14.
Naumovski, Louie, Michael Gordon, Pamela N. Münster, et al.. (2011). A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 2514–2514.
15.
Graham, Richard, Bert L. Lum, Glenn Morrison, et al.. (2011). A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry. Drug Metabolism and Disposition. 39(8). 1460–1467.
16.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Abstract 1310: Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients. Cancer Research. 71(8_Supplement). 1310–1310.
17.
Graham, Richard, Ilsung Chang, Karin Jorga, et al.. (2010). Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects.. Journal of Clinical Oncology. 28(15_suppl). e13009–e13009.
18.
Lum, B., Ilsung Chang, Karin Jorga, et al.. (2010). A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential.. Journal of Clinical Oncology. 28(15_suppl). 2558–2558.
19.
Crul, Mirjam, Peter De Porre, Steven Zhang, et al.. (2006). Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function. Journal of Clinical Oncology. 24(28). 4558–4564.
20.
Chang, Ilsung, et al.. (2005). The effect of surface finishes on flexural strength, fracture toughness of feldspathic dental porcelain. Seoul National University Open Repository (Seoul National University). 43(3). 293–305.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Victor Sandor Breakdown of academic impact, for papers by Jan Willem B. de Groot Breakdown of academic impact, for papers by Kimberly B. Dahlman Breakdown of academic impact, for papers by Caroline Dutriaux Breakdown of academic impact, for papers by Nicholas W. Choong Breakdown of academic impact, for papers by Gabriella Liszkay Breakdown of academic impact, for papers by Michael D. Pickard Breakdown of academic impact, for papers by Frank Wu Breakdown of academic impact, for papers by Lila Adnane Breakdown of academic impact, for papers by Jeff Sosman